Sai Life Sciences Limited share price
NSE: SAILIFE · ISIN INE570L01029
Key numbers
- Market cap
- ₹ 33,821 Cr
- Current price
- ₹ 1,592.20
- 52-week high / low
- ₹ 1,697 / 784
- Stock P/E
- 93.3
- Book value
- ₹ 117.5
- Dividend yield
- 0.00%
- ROCE
- 19.2%
- ROE
- 15.1%
- Debt to equity
- 0.12
- Sales growth (3 yrs)
- 21.3%
- Profit growth (3 yrs)
- 226.9%
- 1-year return
- 78.5%
About Sai Life Sciences Limited
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It offers medicinal chemistry, pharmacokinetics, clinical and commercial manufacturing, and process development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is headquartered in Hyderabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 580 | 496 | 556 | 602 | 554 |
| Operating profit | 158 | 121 | 188 | 177 | 148 |
| Net profit | 88 | 60 | 100 | 104 | 73 |
| EPS (₹) | 4.24 | 2.90 | 4.77 | 4.93 | 3.46 |
Concall summary (2026-08-12)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- For the quarter-ended Q1 FY27, total revenue stood at INR553 crores, representing a year -on-year increase of about 12% compared to INR496 crores in the same quarter last year.
- We continue to add new customers, but returning customers accounted for over 90% of our revenue in FY25 and FY26.
Growth & demand
- Revenue for the quarter grew by 12% year-over-year, supported by growth across two businesses, particularly in the CRO, which grew by 26% year-over- year.
- On a Y-o-Y basis, CRO revenues increased by about 26% while the CDMO revenues grew by around 6%.
Capex & expansion
- As we have discussed in the previous earnings call, we expect a stronger H2 with planned capacity expansion going live in the second half of the year.
- We are working on building new capacity specifically designed for early to mid-stage deliveries and will be an important part of the expansion at our new greenfield manufacturing site.
Risks & challenges
- It must be viewed in conjunction with our business risks that could cause future result performance or achievement to differ significantly from what is expressed or implied by such forward -looking statements.
- From a customer s' standpoint, geopolitical uncertainty and concerns around intellectual property have made India an increasingly important part of their diversification strategies.
Peers in Diagnostics & Research
Data for information only, not investment advice. Prices end of day.